Boehringer Ingelheim has won accelerated FDA approval for its combination HIV drug Aptivus. Release
Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.
The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.
Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.